We report that an environmental agent, bis(2-chloroethoxy)methane (CEM), caused cardiac toxicity in male and female F344 rats and B6C3F1 mice exposed to the chemical by dermal administration at doses of 0, 50, 100, 200, 400 or 600 mg/kg 5 days a week for up to 14 weeks. Treatment-related deaths occurred in 10/10 male and 10/10 female rats at 600 mg/kg, in 2/10 female rats at 400 mg/kg, and in 3/10 female mice at 600 mg/kg. The heart lesions were more severe in rats than mice, and more severe in females than males. In rats, the no-observed-adverse-effect level (NOAEL) for the heart lesions was 200 mg/kg for males and 100 mg/kg for females; in mice, it was more than 600 mg/kg for males and 200 mg/kg for females. Multifocal, widespread vacuolization of the myocytes comprised the main morphological feature of the lesions, and only in rats was it accompanied by mononuclear cell infiltration, myocytic necrosis and atrial thrombosis. Hearts from male rats were immunohistochemically stained for troponin T (cTnT) protein. Loss of cytoplasmic cTnT correlated with histopathological damage only in the 600 mg/kg animals. CEM is metabolized to thiodiglycolic acid, a chemical that causes mitochondrial dysfunction. It is hypothesized that mitochondrial damage leads to the heart toxicity from bis(2-chloroethoxy)methane.
Antman, E.M. (2002). Decision making with cardiac troponin tests [editorial] . N Engl J Med346, 2079—82.
2.
Apple, F.S. (2001). Cardiac TroponinAssays: Analytical issues and clinical reference range cutpoints. Cardiovasc Toxicol1, 93—8.
3.
Bernat, A., and Herbert, J.M. (1994). Effect of various drugs on adriamycin-enhanced venous thrombosis in the rat: Importance of PAF. Thromb Res75, 91—7.
4.
Bleuel, H., Deschl, U., Bertsch, T., Bolz, G., and Rebel, W. (1995). Diagnostic efficiency of troponin T measurements in rats with experimental myocardial cell damage. Exp Toxicol Pathol47, 121—7.
5.
Childs, A.C., Phaneuf, S.L., Dirks, A.J., Phillips, T., and Leeuwenburgh, C. (2002). Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio . Cancer Res62, 4592— 8.
6.
Dunn, O.J. (1964). Multiple comparisons using rank sums. Technometrics6, 241—52.
7.
Dunnett, W. (1955). A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc50, 1095—121.
8.
Environmental Protection Agency (2003). High Production Volume Chemical List. 〈http://www.epa.gov/chemrtk/hpvchmlt.htm〉.
9.
Fujihira, S., Yamamoto, T., Matsumoto, M., Yoshizawa, K., Oishi, Y., Fugii, T., Noguchi, H., and Mori, H. (1993). The high incidence of atrial thrombosis in mice given doxorubicin. Toxicol Pathol21, 362—8.
10.
Green, T., and Hathway, D.E. (1975). The biological fate in rats of vinyl chloride in relation to its oncogenicity. Chem Biol Interact11, 545—62.
11.
Grossblatt, N. (1996). Guide for the Care and Use of Laboratory Animals . National Academy Press, Washington, DC.
12.
Hazardous Substance Database (2002). Hazardous Substances Databases, National Institute of Occupational Safety and Health, Washington, DC.〈http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB〉 .
13.
Herman, E.H., El-Hage, A.N., Ferrans, V.J., and Ardalan, B. (1985). Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicol Appl Pharmacol78, 202—14.
14.
Herman, E.H., Lipshultz, S.E., Rifai, N., Zhang, J., Papoian, T., Yu, Z.X., Takeda, K., and Ferrans, V.J. (1998). Use of cardiac troponin T levels as an indicator of doxorubinin-induced cardiotoxicity. Cancer Res58, 195—7.
15.
Herman, E.H., Zhang, J., Chadwick, D.P., and Ferrans, V.J. (1996). Age dependence of the cardiac lesiosn induced by minoxidil in the rat. Toxicology110, 71—83.
16.
Herman, E.H., Zhang, J., Chadwick, D.P., and Ferrans, V.J. (2000). Comparison of the protective effects of amifostine and dexrazoxane against the toxicty of doxorubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol45, 329—34.
17.
Herman, E.H., Zhang, J., Lipshultz, S.E., Rifai, N., Chadwick, D.P., Takeda, K., Yu, Z.X., and Ferrans, V.J. (1999). Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol17, 2237—43.
18.
Hopkins, P.N., and Williams, R.R. (1981). A survey of 246 suggested coronary risk factors . Atherosclerosis40, 1—52.
19.
Hsu, S., and Raine, L. (1981). Protein A, avidin, and biotin in immunohistochemistry . J Histochem Cytochem29, 1349—53.
20.
Jin, J.P., Huang, Q.A., Yeh, H.I., and Lin, J.J.C. (1992). Complete nucleotide sequence and structural organization of rat cardiac troponin T gene. J Mol Biol227, 1269—76.
21.
Jones, B.K., and Hathway, D.E. (1978). Differences in metabolism of vinylidene chloride between mice and rats. Br J Cancer37, 411—7.
22.
Katus, H.A., Looser, S., Hallermayer, K., Remppis, A., Scheffold, T., Borgya, A., Essig, U., and Geuss, U. (1992). Development and in vitro characterization of a new immunoassay of cardiac troponin T. Clinic Chem38, 383—93.
23.
Katus, H.A., Remppis, A., Neumann, F.J., Scheffold, T., Diederich, K.W., Vinar, G., Noe, A., Matern, G., and Kuebler, W. (1991). Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation83, 902—12.
24.
Kragten, J.A. (1996). Cardiac troponin T release into plasma after acute myocardial infarction: Only fractional recovery compared with enzymes. Ann Clin Biochem33, 314—23.
25.
Lesnefsky, E.J., Moghaddas, S., Tandler, B., Kerner, J., and Hoppel, C.L. (2001). Mitochondrial dysfunction in cardiac disease: Ischemia-reperfusion, aging, and heart failure. J Mol Cell Cardiol33, 1065—89.
26.
Marin-Garcia, J., and Goldenthal, M.J. (2002). Understanding the impact of mitochondrial defects in cardiovascular disease: A review. J Card Failure8, 347—60.
27.
Mathews, J.M., and Jeffcoat, A.R. (2002). Bis(2-chloroethoxy)methane: Comparative metabolism and excretion in rats and mice. NIEHS Contract No. N01-ES-75407 contract with RTI, Research Triangle Park, NC RTI Report No. RTI/64U-6855/14P, Feb 28, 2002.
28.
Mesnard, L., Samson, F., Espinasse, I., Durand, J., Neveux, J., and Mercadier, J. (1993). Molecular cloning and development expression of human cardiac troponin T. Fed Eur Biochem Soc328, 139—44.
29.
National Toxicology Program (1992). Toxicology and Carcinogenesis Studies of Monochloroacetic Acid in F344/N rats and B6C3F1 mice. Research Triangle Park, NC .
30.
National Toxicology Program (2000). Bulk chemical limited analysis report, bis(2-chloroethoxy)methane . NIH Contract No. N01-ES-55397, Task CHEM04776.
31.
National Toxicology Program (2002). 90-day toxicity studies of bis(2-chloroethoxy)methane. Battelle Columbus reports submitted to NTP-G004164-AD & G004164-AE, July and October 2002.
32.
O'Brien, P.J., Dameron, G.W., Beck, M.L., Kang, Y.J., Erickson, B.K., Di Battista, T.H., Miller, K.E., Jackson, K.N., and Mittelstadt, S. (1997). Cardiac troponin T is a sensitive, specific, biomarker of cardiac injury in laboratory animals. Lab Anim Sci47, 486—95.
Pearlstone, J.R., Carpenter, M.R., and Smillie, L.B. (1986). Amino acid sequences of rabbit cardiac troponin T. J Biol Chem261, 16795—810.
35.
Raggi, A., Grand, R.J.A., Moir, A.J.G., and Perry, S.V. (1989). Structure-function relationships in cardiac troponin T. Biochim Biophys Acta997, 135—43.
36.
Ruben, Z., Arceo, R.J., Bishop, S.P., Elwell, M.R., Kerns, W.D., Mesfin, G.M., Sandusky, G.E., and Van Vleet, J.F. (2000). Non-proliferative lesions of the heart and vasculature in rats. CV-1. Guides for Toxicologic Pathology, pp. 1—10. STP/ARP/AFIP.
37.
Shirley, E. (1977). A non-parametric equivalent of William's test for contrasting increasing dose levels of a treatment. Biometrics33, 386—9.
38.
Sorescu, D., and Griendling, K.K. (2002). Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail8, 132—40.
39.
The Joint European Society of Cardiology/American College of Cardiology Committee (2000). Myocardial infaction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infaction . Europ Heart J21, 1502—13.
40.
van Loo, G., Saelens, X., van Gurp, M., MacFarlane, M., Martin, S.J., and Vandenabelle, P. (2002). The role of mitochondrial factors in apoptosis: A Russian roulette with more than one bullet. Cell Death Differ9, 1031—42.
41.
Visarius, T.M., Bahler, H., Kupfer, M.A., Cerny, T., and Lauterburg, B.H. (1998). Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats. Drug Metab Disp26, 193—6.
42.
Wang, X. (2001). The expanding role of mitochondria in apoptosis . Genes Dev15, 2922—2933.
43.
Yllner, S. (1971). Metabolism of chloracetate-1-14C in the mouse . Acta Pharmacol Toxicol30, 69—80.
44.
Yussman, M.G., Toyokawa, T., Odley, A., Lynch, R.A., Wu, G., Colbert, M.C., Aronow, B.J., Lorenz, J.N., and Dorn, G.W.I. (2002). Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med8, 725—30.
